Clinical trial
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive…
NCT00261846 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00261846 |
|---|---|
| Title | Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias |
| Official title | A Phase 1/2 Study Of Bosutinib (Ski-606) In Philadelphia Chromosome Positive Leukemias |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Bosutinib |
| Enrollment | 571 |
| Start date | Jan 18, 2006 |
| Primary completion | Sep 25, 2009 |
| Completion | Aug 6, 2015 |
| First posted | Dec 5, 2005 |
| Last update posted | Jul 27, 2017 |
| Countries | Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Finland, Germany, Hong Kong, Hungary and 15 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: